Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JASPER-reduction Study of peficitinib dose reduction in rheumatoid arthritis
jRCTs051220027Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of peficitinib in rheumatoid arthritis (RA) (2 arms), sponsored by Astellas Pharma. Primary endpoint: Maintenance of DAS28-ESR below 3.2 through 24 weeks. Started Jul 2022; status: active, not recruiting.
02
Drugs
peficitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCTs051220027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051220027.